Sökning: id:"swepub:oai:lup.lub.lu.se:991ff9cc-bb35-467e-96e0-a9d6601c78f7" >
Postprandial Glucag...
Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus : A Post Hoc Analysis
-
- Ahrén, Bo (författare)
- Lund University,Lunds universitet,Diabetes,Forskargrupper vid Lunds universitet,Lund University Research Groups
-
- Galstyan, Gagik (författare)
- National Centre of Endocrinology, Moscow
-
- Gautier, Jean Francois (författare)
- Lariboisière Hospital
-
visa fler...
-
- Giorgino, Francesco (författare)
- University of Bari Aldo Moro
-
- Gomez-Peralta, Fernando (författare)
- Hospital General de Segovia
-
- Krebs, Michael (författare)
- Medical University of Vienna
-
- Nikonova, Elena (författare)
- Artech Information Systems, LLC
-
- Stager, William (författare)
- Sanofi S.A., France
-
- Vargas-Uricoechea, Hernando (författare)
- Hospital Universitario San José
-
visa färre...
-
(creator_code:org_t)
- 2016-06-18
- 2016
- Engelska 8 s.
-
Ingår i: Diabetes Therapy. - : Springer Science and Business Media LLC. - 1869-6953 .- 1869-6961. ; 7:3, s. 583-590
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://link.springe...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction: The extent to which postprandial glucagon reductions contribute to lowering of postprandial glucose in patients with type 2 diabetes mellitus (T2DM) is currently unknown. The aim of this analysis was to determine whether a reduction in postprandial glucagon following treatment with the glucagon-like peptide-1 receptor agonist lixisenatide correlates with a reduction in postprandial glucose and glycated hemoglobin (HbA1c) in patients with T2DM. Methods: A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea [SU] ± metformin). Glucagon levels were assessed 2 h after a standardized meal test performed at baseline and Week 24 and were examined for correlation with changes in 2-h postprandial glucose and HbA1c. Results: Lixisenatide reduced 2-h postprandial glucagon at Week 24 compared with placebo (P < 0.00001). The mean change in postprandial glucagon significantly correlated with reductions in postprandial glucose (P < 0.00001) and HbA1c (P < 0.00001). Conclusion: A reduction in postprandial glucagon following lixisenatide administration correlated with a decrease in postprandial glucose and HbA1c in patients with T2DM insufficiently controlled on metformin and/or SU. This suggests that lowering of postprandial glucagon contributes to the overall glycemic improvement observed with lixisenatide. Funding: Sanofi. Clinical Trial Numbers: NCT00712673 (GetGoal-M) and NCT00713830 (GetGoal-S).
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- Glucagon
- Glucagon-like peptide-1 receptor agonist
- Glycemic control
- Lixisenatide
- Prandial
- Type 2 diabetes mellitus
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas